Stay informed with the latest litigation news. Explore now

IP Verse

Cytokine Derived Treatment With Reduced Vascular Leak Syndrome - EP2986312B1

EP2986312

CYTUNE PHARMA
Application Number
EP14723324A
Filing Date
Apr 22, 2014
Status
Granted And Under Opposition
Nov 12, 2021
Grant Date
Dec 15, 2021
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3995507B1
EP3444271B1
EP3030262B1

Bibliography

The patent EP2986312B1 was granted to Cytune Pharma on Dec 15, 2021 following the initial filing on Apr 22, 2014 under the application number EP14723324A . The current legal status of the patent is Granted And Under Opposition.

Patent Summary

Patent Family New

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

SANOFISep 14, 2022ADMISSIBLE
WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBBSep 14, 2022ADMISSIBLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents